Gamida Cell Ltd., otherwise known as GMDA, has announced that it is currently considering several strategic options to increase value for all its stakeholders. These options might be led towards an asset sale, a merger, or another kind of strategic business deal.
Furthermore, the focus and resources of the company are being continually invested into the commercialisation of Omisirge, which is the only cell therapy donor source modified by nicotinamide that has received FDA approval. This approval has been specifically granted for use in allogeneic stem cell transplants.
As a pioneer in cell therapy, Gamida Cell is making strides in developing cells into powerful therapeutic tools. Its implementation of nicotinamide technology takes advantage of NAM's properties to expand and enhance cells. Consequently, this has led to the creation of allogeneic cell therapy products and potential candidates that could in the future offer a cure to patients afflicted with hematologic malignancies.
For similar health news, refer to rttnews.com.
